Method of treating rash in patients undergoing anti-EGFR therapy
US9428582B2 · kind B2 · utility
3Cited by
46References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 3, 2007 |
| Grant date | Aug 30, 2016 |
| Priority date | — |
| Expiry date | Sep 7, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/507
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.